Kelly Parish, a 32-year-old talent executive from Sunderland, transformed her health with Mounjaro (tirzepatide), a GLP-1/GIP medication. Starting in October 2024 at over 15.5 stone and size 18, she dropped to 11st 7lbs and size 12 by July 2025. Previously at risk for type 2 diabetes, she credits the drug for her success after years of struggling.
Kelly's Initial Success on Mounjaro
Kelly lost over four stone on Mounjaro, reaching a comfortable weight. The medication curbed her overeating habits, where she once consumed dinners followed by takeaways without feeling full. Her pounds dropped steadily, improving her health outlook.
Challenges After Weaning Off Mounjaro
Thrilled with results, Kelly weaned off Mounjaro, hoping to maintain her figure independently. Within 20 days, the drug left her system, unleashing "insane" food noise. Old habits returned, leading to a 9lb gain in weeks despite gym activity and calorie counting.
- Cravings for desserts and sweets emerged, unlike her pre-quit self.
- Late-night snacking derailed progress.
- She felt like a "child without a parent," missing the drug's guidance.
Internal Battle and Decision to Return
Kelly battled voices urging her back on Mounjaro while fearing judgment as a failure. Prices had risen, but reality hit: she needed it. In October 2025, she restarted with a smarter approach—using it as a guide alongside calorie tracking and exercise.
New Strategy and Current Dosage
Beginning at the lowest dose, Kelly allowed her body to adjust before increasing to 5mg, where she remains. This balances cardio, strength training, and high-protein intake, avoiding past over-reliance. Apps like Shotlee can help track GLP-1 doses for consistency.
